We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Marina Biotech Closes Previously Announced $5 Million Financing
News

Marina Biotech Closes Previously Announced $5 Million Financing

Marina Biotech Closes Previously Announced $5 Million Financing
News

Marina Biotech Closes Previously Announced $5 Million Financing

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Marina Biotech Closes Previously Announced $5 Million Financing"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Marina Biotech, Inc. has announced that it has completed the closing of the previously announced equity investment of up to $5 million with Socius CG II, Ltd. ("Socius"), a Bermuda-based subsidiary of Socius Capital Group, LLC, and will be filing a registration statement on Form S-3 to register the shares for resale by Socius.

Once the S-3 is filed and declared effective by the U. S. Securities and Exchange Commission, and subject to the satisfaction of the other conditions set forth in the Securities Purchase Agreement between the Company and Socius, the funds available under the agreement will be accessible by the Company.

"This unique financing structure permits us to access funds as they are required in the near future," stated J. Michael French, President and Chief Executive Officer at Marina Biotech, Inc.

French continued, "With what we believe is the most unique and broadest nucleic acid drug discovery platform in the industry, we want to ensure we have the necessary funds to continue to execute on our business strategy. In 2011, we established ourselves broadly across the oligonucleotide therapeutic space with two technology deals (an RNAi drug discovery partnership with The Debiopharm Group and a microRNA delivery license with Mirna Therapeutics) as well as two separate nucleic acid technologies in clinical development (liposomal delivery of a single-stranded DNA through a license with ProNAi Therapeutics and our own on-going START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis) clinical trial with CEQ508). We feel access to these funds will give us the necessary financial flexibility to continue to execute on our pre-clinical, clinical and partnering objectives."

Advertisement